Preparation method and application of pig IKK alpha polyclonal antibody
The invention discloses a preparation method and application of a pig IKK alpha polyclonal antibody, and belongs to the technical field of biology. The preparation method comprises the following steps: after IKK alpha recombinant protein and a freund's adjuvant are equivalently mixed and emulsified, immunizing an animal to obtain a polyclonal antibody; wherein the amino acid sequence of the IKK alpha recombinant protein is as shown in SEQ ID NO: 1. The specific polyclonal antibody is prepared by constructing prokaryotic and eukaryotic expression vectors of the pig-derived IKK alpha gene, the polyclonal antibody is verified to be capable of being specifically combined with the protein of the IKK alpha factor, and the protein expression level of the IKK alpha factor is remarkably improved after PK-15 cells are infected by CSFV. Therefore, the polyclonal antibody prepared by the invention can be applied to detection or diagnosis of CSFV, and also lays a foundation for deep exploration and understanding of interaction of CSFV and IKKalpha protein and functions and cellular immune mechanisms of CSFV and IKKalpha protein in an NF-kappa B signal channel..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LUO TINGRONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-03-21, Last update posted on www.tib.eu: 2023-06-21, Last updated: 2023-06-30 |
|---|
| Patentnummer: |
CN115819603 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017301971 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017301971 | ||
| 003 | DE-627 | ||
| 005 | 20230630120737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230623s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017301971 | ||
| 035 | |a (EPA)CN115819603 | ||
| 035 | |a (EPA)85518224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LUO TINGRONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation method and application of pig IKK alpha polyclonal antibody |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-03-21, Last update posted on www.tib.eu: 2023-06-21, Last updated: 2023-06-30 | ||
| 520 | |a The invention discloses a preparation method and application of a pig IKK alpha polyclonal antibody, and belongs to the technical field of biology. The preparation method comprises the following steps: after IKK alpha recombinant protein and a freund's adjuvant are equivalently mixed and emulsified, immunizing an animal to obtain a polyclonal antibody; wherein the amino acid sequence of the IKK alpha recombinant protein is as shown in SEQ ID NO: 1. The specific polyclonal antibody is prepared by constructing prokaryotic and eukaryotic expression vectors of the pig-derived IKK alpha gene, the polyclonal antibody is verified to be capable of being specifically combined with the protein of the IKK alpha factor, and the protein expression level of the IKK alpha factor is remarkably improved after PK-15 cells are infected by CSFV. Therefore, the polyclonal antibody prepared by the invention can be applied to detection or diagnosis of CSFV, and also lays a foundation for deep exploration and understanding of interaction of CSFV and IKKalpha protein and functions and cellular immune mechanisms of CSFV and IKKalpha protein in an NF-kappa B signal channel. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI XIAONING |4 aut | |
| 700 | 0 | |a JIN YIXIN |4 aut | |
| 700 | 0 | |a ZHAO XIANGXIU |4 aut | |
| 700 | 0 | |a HUANG MAOFA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. März |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85518224/publication/CN115819603A1?q=CN115819603 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 21 |c 03 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 03 | ||